Total Current Assets Total Assets Related and Nonrelated Parties [Axis] Total Current Liabilities Total Liabilities Total Stockholders’ Equity Balance Balance Total Liabilities and Stockholders’ Equity Gross Profit Total Operating Expenses Operating Loss Total Other Income (Expense), Net Loss before Income Taxes Net Loss Net loss Statement of Stockholders' Equity [Abstract] Balance (in Shares) Balance (in Shares) Equity Components [Axis] Net Cash (Used In) Provided By Operating Activities Net Cash Used In Investing Activities Net Cash Provided by Financing Activities Net Change in Cash and Cash Equivalents Cash and Cash Equivalents – Beginning of Period Cash and Cash Equivalents – End of Period Nature of Operations, Basis of Presentation and Summary of Significant Accounting Policies [Abstract] Going Concern Uncertainty and Management’s Plan [Abstract] Revenue Recognition and Accounts Receivable [Abstract] Schedule of Estimated co-Pay Assistance Reflected and Included in the Gross-to-Net Adjustments [Abstract] Net Revenue Revenues Inventory [Abstract] Schedule of Inventory [Abstract] Total Inventory Prepaid Expenses [Abstract] In-Process Research and Development, Net [Abstract] Total In process research and development net Intangible Asset, Indefinite-Lived, Class [Axis] Patent and Technology License Agreements [Abstract] Loan Agreement [Abstract] Schedule of Loan Agreement [Abstract] Notes payable, net of deferred financing costs Stockholders’ Equity [Abstarct] Schedule of Option Activity [Abstract] Shares, Outstanding beginning balance Shares, Outstanding ending balance Weighted-Average Exercise Price, Outstanding beginning balance Weighted-Average Exercise Price, Outstanding ending balance Aggregate Intrinsic Value, Outstanding beginning balance Aggregate Intrinsic Value, Outstanding ending balance Class of Warrant or Right [Axis] Award Type [Axis] Commercial Manufacturing Contracts [Abstract] Related Party Transactions [Abstract] Gain on Sale of New Jersey Net Operating Losses [Abstract] Nasdaq Listing [Abstract] Current Assets: Cash and cash equivalents Accounts receivable, net of allowances Prepaid expenses Other Assets: In-process research and development, net of accumulated amortization LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities: Accounts payable License payable Accrued expenses Due to related party Notes payable, net of deferred financing costs Deferred tax liability Note payable to related party Stockholders’ Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding Preferred stock, par value (in Dollars per share) Preferred stock par value (in Dollars per share) Preferred stock, shares authorized (in Shares) Preferred stock authorized Preferred stock, shares issued (in Shares) Preferred stock, shares outstanding (in Shares) Common stock - $0.0001 par value; 400,000,000 shares authorized at June 30, 2026 and September 30, 2025; 105,758,982 and 83,513,442 shares issued and outstanding at June 30, 2026 and September 30, 2025, respectively Common stock, par value (in Dollars per share) Common stock par value (in Dollars per share) Common stock, shares authorized (in Shares) Common stock authorized Common stock, shares issued (in Shares) Common stock, shares outstanding (in Shares) Additional paid-in capital Additional paid in capital Accumulated deficit Operating Expenses Research and development Amortization of in-process research and development Amortization of research and development process General and administrative Stock-based compensation – general and administrative Stock-based compensation expense Other Income (Expense) Interest income Gain on sale of New Jersey net operating losses Income tax expense (benefit) Net Loss Per Share - Basic (in Dollars per share) Net Loss Per Share – Diluted (in Dollars per share) Weighted Average Common Shares Outstanding Weighted Average Common Shares Outstanding – Basic (in Shares) Weighted Average Common Shares Outstanding – Diluted (in Shares) December 2025 sale of common stock and pre-funded warrants, net of costs of $2,872,989 December 2025 sale of common stock and pre-funded warrants, net of costs of $2,872,989 (in Shares) December 2025 sale of common stock and pre-funded warrants, net of costs Stock-based compensation expense Proceeds from exercise of pre-funded warrants Proceeds from exercise of pre-funded warrants (in Shares) Pre-funded warrants were exercised December 2025 offering costs Net proceeds from exercise of warrants Net proceeds from exercise of warrants (in Shares) Issuance of warrants for loan agreement Cash Flows From Operating Activities: Adjustments to reconcile net loss to net cash used in operating activities: Amortization of deferred financing costs Amortization of deferred financing costs Deferred income tax expense Changes in operating assets and liabilities: Accounts payable Accrued expenses Due to related party Cash Flows From Investing Activities Cash Flows From Financing Activities Net proceeds from notes payable Additional payable Net proceeds from exercise of warrants and pre-funded warrants Gross proceeds from offering (in Dollars) Net proceeds from issuance of common stock Supplemental Disclosures of Cash Flow Information and Non-cash Transactions: Interest Paid Warrants issued for loan agreement included in deferred financing costs Deferred financing costs included in accrued expenses Cost of revenues Interest expense Interest expense Accounts receivable, net of allowances Inventory Prepaid expenses License payments Deferred Financing Costs Related Party Preferred Stock Preferred Stock [Member] Common Stock Common Stock [Member] Additional Paid-In Capital Accumulated Deficit NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES GOING CONCERN UNCERTAINTY AND MANAGEMENT’S PLAN REVENUE RECOGNITION AND ACCOUNTS RECEIVABLE Schedule of Estimated co-Pay Assistance Reflected and Included in the Gross-to-Net Adjustments Gross Product Revenue Gross-to-net adjustments: INVENTORY Schedule of Inventory Finished goods Work in process PREPAID EXPENSES IN-PROCESS RESEARCH AND DEVELOPMENT, NET Schedule of In-Process Research and Development 2026 (excluding the nine months ended June 30, 2026) 2027 2028 2029 2030 2031 Thereafter PATENT AND TECHNOLOGY LICENSE AGREEMENTS LOAN AGREEMENT Schedule of Loan Agreement Notes payable principal balance STOCKHOLDERS’ EQUITY Schedule of Option Activity Weighted-Average Remaining Contractual Term, Outstanding beginning balance Weighted-Average Remaining Contractual Term, Outstanding ending balance Shares, Granted Weighted-Average Exercise Price, Granted Shares, Forfeited Weighted-Average Exercise Price, Forfeited Shares, Exercisable Weighted-Average Exercise Price, Exercisable Weighted-Average Remaining Contractual Term, Exercisable Aggregate Intrinsic Value, Exercisable Schedule of Warrants Outstanding Exercise price (in Dollars per share) Exercise price per share (in Dollars per share) Number Common stock reserved Expiration Dates Schedule of Common Stock Reserved for Future Issuances Common stock reserved for future issuances Aggregate shares of common stock COMMERCIAL MANUFACTURING CONTRACTS RELATED PARTY TRANSACTIONS GAIN ON SALE OF NEW JERSEY NET OPERATING LOSSES NASDAQ LISTING Deferred financing costs, net of accumulated amortization In Process Research and Development [Member] July 2025 Offering Agent [Member] July 2025 Prior Offering Agent [Member] September 2025 Offering Agent [Member] September 2025 Prior Offering Agent [Member] December 2025 Offering Investors [Member] December 2025 Offering Investors [Member] December 2025 Placement Offering Agent [Member]